High cell-free dna levels in cerebrospinal fluid predict leptomeningeal seeding of hematologic malignancy

3Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background and Purpose The main difficulty when diagnosing leptomeningeal metastases (LMSs) is the low sensitivity of cytology. Cancer cells release cell-free DNA (cfDNA) during proliferation and apoptosis, and so we analyzed the cfDNA level as a biomarker for LMSs in hematologic malignancy. Methods This study prospectively enrolled 20 patients with hematologic malignancy who underwent cerebrospinal fluid (CSF) analysis. LMS was diagnosed based on both CSF cytology and clinical findings. Results The CSF level of cfDNA was higher in patients with LMSs (108.17±84.84 ng/mL, mean±standard deviation) than in non-LMS patients (14.23±2.78 ng/mL). The sensitivity of cfDNA was higher than that of cytology (100% vs. 87%). Conclusions The cfDNA level in the CSF can be used as a supplemental marker for diagnosing LMS in hematologic malignancy patients.

Cite

CITATION STYLE

APA

Kim, E. Y., Lee, S. T., Kim, Y. S., Byun, J. M., Hong, J., Shin, D. Y., … Kim, I. (2020). High cell-free dna levels in cerebrospinal fluid predict leptomeningeal seeding of hematologic malignancy. Journal of Clinical Neurology (Korea), 16(4), 581–585. https://doi.org/10.3988/jcn.2020.16.4.581

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free